je.st
news
Tag: 58th
Sylvan-Highlands | 01-04-10 | 1512 SW 58th Ave | Pre-Application Conference - NOTICE | EA 18-279165
2019-01-03 23:25:27| PortlandOnline
PDF Document, 3,653kbCategory: Pre-Application Conferences
Tags: notice
conference
ea
ave
SE Foster Rd from SE 58th to SE 70th Ave
2018-10-15 21:11:16| PortlandOnline
Construction - maintenance of existing water facilities 10/19 - 10/21 PDF Document, 537kbCategory: Inner Southeast Portland (SEUL)
Sylvan-Highlands | 12-13-17 | 1512 SW 58th Ave | Pre-Application Conference - NOTICE | EA 17-278668
2017-12-13 18:19:33| PortlandOnline
PDF Document, 773kbCategory: Pre-Application Conferences
Tags: notice
conference
ea
ave
ROW - E Burnside between SE 56th and NE 58th Aves
2017-10-06 20:52:18| PortlandOnline
Construction - Installing service to townhouses up to 1 week between 10/17 and 12/17 PDF Document, 558kbCategory: Inner Southeast Portland (SEUL)
KEYTRUDA (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology
2016-12-06 01:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Data from Pivotal KEYNOTE-087 Trial Show Overall Response Rate (ORR) of 69.0 Percent and Complete Remission Rate (CRR) of 22.4 Percent With More than Two Years of Follow-up, Findings from KEYNOTE-013 Show ORR of 58 Percent and CRR of 19 Percent with Responses of 12 Months or Greater in 70 Percent of Responding Patients KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today updated findings evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in two trials of patients with relapsed or refractory classical Hodgkin lymphoma (cHL). In the KEYNOTE-087 and KEYNOTE-013 trials, KEYTRUDA demonstrated overall response rates (ORR) of 69.0 percent and 58 percent, respectively. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: of
results
american
society